<p>Accounting for the Cost of AMR (Approach 1).</p>

Raymond Oppong's study, last updated in April 2026, presents a model-based cost-utility analysis of the Biofire Film Array Respiratory Panel RP 2.1+ test for patients with chronic obstructive pulmonary disease (COPD). The 5.5 KB Excel file contains results from a 40-year healthcare perspective model, evaluating the test's cost-effectiveness and the potential impact of accounting for antimicrobial resistance (AMR) costs. The analysis indicates the test is cost-saving, with potential annual savings estimated between £118 million and £18.6 billion.

Use Cases

• Training or validating health economic models based on the described 40-year cost-utility framework.
• Analyzing the financial impact of diagnostic testing on antibiotic prescription patterns and AMR costs.
• Benchmarking cost-effectiveness results for respiratory infection diagnostics against the reported £2762.40 cost difference and 0.03 QALY gain.

Strengths

• Model parameters were informed by a targeted literature review and expert opinions, suggesting a structured methodology.
• The analysis explicitly attempts to account for antimicrobial resistance costs using two distinct approaches.
• The dataset is openly licensed under CC-BY-4.0, facilitating reuse and sharing.

Limitations

• Row count and column-level documentation are absent; field semantics must be inferred after download.
• The dataset is very small (5.5 KB), indicating it likely contains summary model outputs rather than raw or granular patient-level data.
• The description metadata is limited; actual data structure and quality require manual inspection of the Excel file.

Provenance

Source

Raymond Oppong via figshare

Collection Method

Model-based cost-utility analysis informed by a targeted literature review and expert opinions.

Time Range

Model horizon of 40 years.

Freshness

Last updated 2026-04-27 17:26:53; freshness should be verified.

Geography

null